Study of a new drug to prevent severe immune reaction after cord blood transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a monoclonal antibody (CD25) to standard therapy can reduce severe acute GVHD (a serious immune reaction) after umbilical cord blood transplant for blood cancers. It aims to improve outcomes for patients with malignant hematologic diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer like leukemia or lymphoma
- You are scheduled for an umbilical cord blood transplant
- If you can become pregnant, you must have a negative pregnancy test and use effective birth control for one year
- You have not had a prior stem cell or organ transplant
- You do not have an uncontrolled infection, HIV, or active hepatitis B or C
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This trial tests a new drug called axatilimab, given alongside standard care, to help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for people who are planning a first transplant from a matched donor.
This trial tests whether adding abatacept to a double cord blood transplant can prevent graft-versus-host disease (GVHD) in people with certain blood cancers. You may qualify if you have high-risk leukemia or other blood disorders and do not have a matched related or unrelated donor.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.